In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Guo, Na ^a   Ling, Guanghui ^b   Liang, Xiaoying ^a   Jin, Jing ^a   Fan, Junwen ^c   Qiu, Jiazhang ^a   Song, Yu ^a   Huang, Ning ^a   Wu, Xiuping ^a   Wang, Xuelin ^a   Deng, Xuming ^a   Deng, Xuliang ^b   Yu, Lu ^a  

^a JILIN UNIVERSITY   (China)

^b PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Antifungal susceptibility; Candida albicans; Chequerboard method; Pseudolaric acid B; Synergy; Time kill curves

Indexed keywords

FLUCONAZOLE; PSEUDOLARIC ACID B;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; DRUG EFFECT; DRUG POTENTIATION; FUNGUS GROWTH; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PINACEAE; PRIORITY JOURNAL; PSEUDOLARIX KAEMPFERI;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DITERPENES; DRUG SYNERGISM; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; TIME FACTORS;

CANDIDA ALBICANS; PSEUDOLARIX KAEMPFERI;

EID: 80052784632     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01935.x     Document Type: Article

References (26)

1. Sims CR, Ostrosky ZL, Rex JH. Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res 2005; 36: 660-71.
2. Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008; 83: 1011-21.
3. Georgopapadakou NH, Tkacz JS. The fungal cell wall as a drug target. Trends Microbiol 1995; 3: 98-104.
4. Rex JH, Walsh TJ, Sobel J et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
5. Masia Canuto M, Gutierrez-Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002; 2: 550-63.
6. Priya U, Jeniel N, Joseph H, David A. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 2008; 52: 1127-32.
7. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002; 49: 345-51.
8. Yang SP, Wang Y, Wu Y, Yue JM. Five new diterpenoids from Pseudolarix kaempferi. J Nat Prod 2002; 65: 1041-44.
9. Erguang L, Alice MC, Charles DH. Antifungal evaluation of pseudolaric acid B, a major constituent of Pseudolarix kaempferi. J Nat Prod 1995; 58: 57-67.
10. Quan H, Cao YY, Xu Z et al. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole. Antimicrob Agents Chemother 2006; 50: 1096-99.
11. Nooney L, Matthews RC, Burnie JP. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis 2005; 51: 19-29.
12. National Committee for Clinical and Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard. M27-A. Wayne, PA: National Committee for Clinical and Laboratory Standards, 1997
13. Sun S, Li Y, Guo Q, Shi C, Yu J, Ma L. In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob Agents Chemother 2008; 52: 409-17.
14. Li Y, Sun S, Guo Q et al. In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. J Antimicrob Chemother 2008; 61: 577-85.
15. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47: 106-17.
16. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
17. Prichard MN, Prichard LE, Shipman CJ. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 1993; 37: 540-45.
18. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997; 41: 1392-95.
19. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 2000; 44: 2373-81.
20. Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol 2002; 51: 105-9.
21. Tang JH, Zhang XX, Liu W, Wang GL. Study on fungistasis action and ultrastructure of Pseudolarix kaempferi Gord. J Liaoning Normal Univ (Nat Sci Edn) 2005; 28: 339-41.
22. Vincent KWW, Pauline C, Stephen SMC et al. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 2005; 11: 6002-11.
23. Guo Q, Sun S, Yu J, Li Y, Cao L. Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time-kill methods. J Med Microbiol 2008; 57: 457-62.
24. Arai R, Sugita T, Nishikawa A. Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans. Mycoses 2005; 48: 38-41.
25. Sun L, Sun S, Cheng A, Wu X, Zhang Y, Lou H. In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans. Antimicrob Agents Chemother 2009; 53: 1586-91.
26. Afeltra J, Vitale RG, Mouton JW, Verweij PE. Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother 2004; 48: 1335-43.